Evidence map›Paper›PMID 39886291›Full record

ArticleMediterranean journal of rheumatology2024

Long-Term Follow-Up of Patients with Axial Spondyloarthritis in Real-Life Setting: Results from Greece of the Multi-Country Registry Proof Study.

Gkikas Katsifis, Andreas Bounas, Anna Kandyli, Maria Koronaiou, Tina Antachopoulou, Antonios Kyriakakis, Dimos Patrikos

Abstract read
In one paragraph

Article in Mediterranean journal of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gkikas KatsifisNavl Hospital, Athens, Greece.
Andreas BounasOLYMPION Hospital-General Clinic of Patras, Patras, Greece.
Anna KandyliPrivate Practice, Athens, Greece.
Maria KoronaiouMedical Department, AbbVie Pharmaceuticals S.A., Neo Iraklio, Athens, Greece.
Tina AntachopoulouMedical Department, AbbVie Pharmaceuticals S.A., Neo Iraklio, Athens, Greece.
Antonios KyriakakisMedical Department, AbbVie Pharmaceuticals S.A., Neo Iraklio, Athens, Greece.
Dimos Patrikos"Metropolitan" General Hospital, Piraeus, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The aim of the present analysis was to describe the clinical and demographic characteristics of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients from Greece who were enrolled in the global PROOF study, and their longitudinal follow-up over 5 years to determine the impact of the disease on quality of life and patient-reported outcomes. Methods: PROOF was an observational study that enrolled recently diagnosed (<1 year) patients fulfilling the Assessment of SpondyloArthritis International Society classification criteria from rheumatology clinical practices from 29 countries across 6 different geographical regions. Results: Of the 100 Greek patients enrolled, 85 were classified based on local (investigator) evaluation of sacroiliac radiographs [AS: 56 (65.88%); nr-axSpA: 29 (34.12%)]. Higher prevalence of males in the AS (approximately 70%) and equal gender representation in the nr-axSpA patients were observed. There were variations in the clinical presentation, symptom duration, mean age at baseline, and HLA-B27 positivity between male and female patients. The majority of the patients were treated with TNF inhibitors from baseline to study end. Disease activity as well as patient-reported outcomes (functional index, quality of life, patient assessment of disease, and work productivity for employed patients) improved compared to baseline. Only 4 patients progressed to AS during the study. Conclusions: This analysis provides longitudinal data from the patients enrolled in the global PROOF study from Greece for comparative purposes. The data from the Greek cohort can highlight challenges in the management of the SpA patients.

Indexed as

axial spondyloarthritis (axSpA)disease activitydisease progressionreal-life

Identifiers

PMID39886291
PMCPMC11778611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.